COVID-19 in Patients with Primary Immunodeficiency

Esenboğa, Saliha; Ocak, Melike; Akarsu, Ayşegül; Bildik, Hacer Neslihan; Çağdaş, Deniz; Topeli, Arzu; Tezcan, İlhan

doi:10.1007/s10875-021-01065-9

Cited by 43 publications

(110 citation statements)

References 15 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Current data also suggests individuals with some immunodeficiency disorders are at increased risk of severe outcomes ( 12 , 13 ). Patients with innate immune defects and T cell disorders are at greater risk than healthy individuals ( 14 – 16 ). In contrast, most studies indicate patients with X-linked agammaglobulinemia (XLA) without comorbidities appear to be at lower risk, inferring antibodies can in some circumstances be detrimental ( 17 – 20 ).…”

Section: Patients At Increased Riskmentioning

confidence: 99%

Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients

et al. 2022

View full text Add to dashboard Cite

Section: Patients At Increased Riskmentioning

confidence: 99%

Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients

et al. 2022

View full text Add to dashboard Cite

“…The patient's hospitalization was complicated by a mild COVID-19 infection. In literature, three patients with STAT 1 GOF mutations had mild COVID-19 disease, [15][16][17] suggesting that STAT1 GOF mutations are not associated with severe COVID-19 infection. [15][16][17] Further research may be conducted to determine the effect of STAT1 GOF on the severity of COVID-19 infection.…”

Section: Discussionmentioning

confidence: 99%

A child with bronchiectasis, chronic mucocutaneous candidiasis, and hypothyroidism secondary to STAT1 gain‐of‐function mutation: A case report and review of the literature

Alidrisi

Maksood

Alqahtani

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Data on the impact of COVID-19 on patients with primary immune deficiencies include primarily adult patients, which may overestimate the risk of severe disease for children, but the rate of severe outcomes seems higher compared with the general population [ 42 , 43 ]. Based on clinical experience and limited published data, patients with severe antibody deficiency or lymphocyte dysfunction appear to be at the highest risk, and mAb therapy for adolescents with these conditions is suggested [ 44 ].…”

Section: Evidence Summarymentioning

confidence: 99%

Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents

Wolf

Abzug

Anosike

et al. 2022

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

Background Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), bamlanivimab and etesivimab, casirivimab and imdevimab (REGEN-COV), and sotrovimab, for treatment or postexposure prophylaxis of Coronavirus disease 2019 (COVID-19) in adolescents (≥12 years of age) and adults with certain high-risk conditions. Previous guidance is now updated based on new evidence and clinical experience. Methods A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacotherapy, and pediatric critical care medicine from 18 geographically diverse US institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on a review of the best available evidence and expert opinion. Results The course of COVID-19 in children and adolescents is typically mild, though more severe disease is occasionally observed. Evidence supporting risk stratification is incomplete. Randomized controlled trials have demonstrated the benefit of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific monoclonal antibody therapies in adults, but data on safety and efficacy in children or adolescents are limited. Potential harms associated with infusion reactions or anaphylaxis are reportedly low in adults. Conclusions Based on evidence available as of August 31, 2021, the panel suggests a risk-based approach to administration of SARS-CoV-2 monoclonal antibody therapy. Therapy is suggested for the treatment of mild to moderate COVID-19 in adolescents (≥12 years of age) at the highest risk of progression to hospitalization or severe disease. Therapeutic decision-making about those at moderate risk of severe disease should be individualized. Use as postexposure prophylaxis could be considered for those at the highest risk who have a high-risk exposure but are not yet diagnosed with COVID-19. Clinicians and health systems should ensure safe and timely implementation of these therapeutics that does not exacerbate existing healthcare disparities.

show abstract

COVID-19 in Patients with Primary Immunodeficiency

Cited by 43 publications

References 15 publications

Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients

Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients

A child with bronchiectasis, chronic mucocutaneous candidiasis, and hypothyroidism secondary to STAT1 gain‐of‐function mutation: A case report and review of the literature

Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents

Contact Info

Product

Resources

About